A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Avacopan (Primary)
- Indications Hidradenitis suppurativa
- Focus Registrational; Therapeutic Use
- Acronyms AURORA
- Sponsors ChemoCentryx
- 04 Nov 2019 According to an ChemoCentryx media release, this study is progressing well, with almost 80 percent of sites now activated and over 55 percent of patients enrolled to date.
- 05 Aug 2019 According to a ChemoCentryx media release, the company announced the acceleration in site activation and patient enrollment . 50% sites are now activated and approximately 25% patients enrolled to date.
- 06 May 2019 According to a ChemoCentryx media release, data from this registration-supporting trial is expected in 2020.